These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20559037)

  • 21. Effects of highly active antiretroviral therapy on vaccine-induced humoral immunity in HIV-infected adults.
    González R; Castro P; García F; Plana M; Bayas JM; Lafuente S; Serrano B; Mora B; Argelich R; Gatell JM; Vilella A
    HIV Med; 2010 Sep; 11(8):535-9. PubMed ID: 20408890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.
    Offersen R; Melchjorsen J; Paludan SR; Østergaard L; Tolstrup M; Søgaard OS
    Hum Vaccin Immunother; 2012 Aug; 8(8):1042-7. PubMed ID: 22854665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
    Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
    J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.
    Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
    Scand J Immunol; 2009 Mar; 69(3):194-202. PubMed ID: 19281531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunization against pneumococcal disease in HIV-infected patients: conjugate versus polysaccharide vaccine before or after reconstitution of the immune system (CTN-147).
    Slayter KL; Singer J; Lee TC; Kayhty H; Schlech WF
    Int J STD AIDS; 2013 Mar; 24(3):227-31. PubMed ID: 23535358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.
    Puumalainen T; Dagan R; Wuorimaa T; Zeta-Capeding R; Lucero M; Ollgren J; Käyhty H; Nohynek H
    Pediatr Infect Dis J; 2003 Feb; 22(2):141-9. PubMed ID: 12586978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of antiretroviral therapy on immunogenicity of simultaneous vaccinations against influenza, pneumococcal disease and hepatitis A and B in human immunodeficiency virus positive individuals.
    Horster S; Laubender RP; Lehmeyer L; Ankerst DP; Eberle J; Reinert R; Imöhl M; van der Linden M; Schweiger B; Bogner JR
    J Infect; 2010 Dec; 61(6):484-91. PubMed ID: 20875454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discontinuing Pneumocystis carinii prophylaxis.
    Girard PM
    N Engl J Med; 2001 Jan; 344(3):222-3. PubMed ID: 11172146
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998--2003.
    Teshale EH; Hanson D; Flannery B; Phares C; Wolfe M; Schuchat A; Sullivan P
    Vaccine; 2008 Oct; 26(46):5830-4. PubMed ID: 18786586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
    Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
    Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant.
    Wuorimaa T; Dagan R; Väkeväinen M; Bailleux F; Haikala R; Yaich M; Eskola J; Käyhty H
    J Infect Dis; 2001 Nov; 184(9):1211-5. PubMed ID: 11598848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influenza vaccination of human immunodeficiency virus 1-infected patients receiving antiretroviral therapy.
    Banic S; Koren S; Tomazic J; Vidmar L; Ihan A; Poljak M; Avsic-Zupanc A
    Acta Virol; 2001 Feb; 45(1):39-44. PubMed ID: 11394576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.
    Scott DA; Komjathy SF; Hu BT; Baker S; Supan LA; Monahan CA; Gruber W; Siber GR; Lockhart SP
    Vaccine; 2007 Aug; 25(33):6164-6. PubMed ID: 17629361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.